Representative Matters
Repräsentative Angelegenheiten
代表事项
Patent Counseling
- Proteostasis Therapeutics on patent prosecution matters and strategy relating to its cystic fibrosis transmembrane regulator small molecule program, including patent matters related to its $50 million initial public offering and $65 million follow-on public offering
- Aptinyx on patent matters relating to NMDA small molecule modulators, including patent matters related to its $65 million Series A financing
- Zafgen Inc. on patent portfolio strategy and patent matters relating to its MetAP-2 inhibitor small molecule program and its $96 million public offering and subsequent $137 million follow-on public offering
- Nogra Pharma Ltd. (Ireland) on patent portfolio strategy and patent matters relating to small molecule therapeutics including PPARg modulators; IL-34 technology; and SMAD7 antisense therapy.
- AMAG Pharmaceuticals on patent matters relating to its marketed products and its $201 million follow-on and $225 convertible note offerings
- Aegerion Pharmaceuticals on patent matters relating to the approved small molecule lomitapide and BLA approved product metreleptin
- Neuroderm Ltd. (Israel) on patent matters relating to its CNS small molecule therapeutics and its IPO and recent follow-on offering
- Full life cycle patent strategy on behalf of a pharmaceutical company with a recently approved orphan drug
- Early stage platform and discovery stage patent strategies for several pharmaceutical and biological therapeutic companies
- Post grant review challenges on patents relating to approved products
- Preparation of the published patent application that includes the CAS Registry 100 millionth substance, (4S)-6-(4-chlorophenyl)-N-ethyl-8-[2-[[4[hydroxydimethylsilyl)-methyl]benzoyl]amino]ethoxy]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide
Patent Due Diligence/M&A
- Nogra Pharma Ltd. (Ireland) on patent portfolio strategy and patent matters relating to its agreement with Celgene Corporation for an oral, SMAD7 antisense therapy for Crohn’s disease; the agreement includes one of the largest upfront payments for a licensing deal in the last 10 years
- Aegerion Pharmaceuticals on patent matters related to its merger with Novelion (QLT)
- Naurex Inc. on patent portfolio development and patent matters relating to its NMDA small molecule and peptidyl programs and in connection with its recent $560 million merger with Allergan PLC
- BIND Therapeutics on patent matters relating to its nanomedicine platform, its initial public offering on the NASDAQ Stock Market and its subsequent acquisition by Pfizer
- Avila Therapeutics on patent matters relating to its merger with Celgene Corporation
Professional Activities
Dr. Kavanaugh is a member of the American Intellectual Property Law Association, the Boston Patent Law Association and the American Chemical Society.
